Olutasidenib is a selective, small-molecule inhibitor of the mutated IDH1 enzyme with the therapeutic capability to restore regular cellular differentiation, and has been approved for elderly or unfit patients with AML as a first-line treatment together with azacitidine [38]. This evidence concerns the gene IDH1 and acute myeloid leukemia.